Modality
ERT
MOA
STINGag
Target
TIM-3
Pathway
NF-κB
NarcolepsyPancreatic CaPBC
Development Pipeline
Preclinical
~Feb 2016
→ ~May 2017
Phase 1
Aug 2017
→ Aug 2027
Phase 1Current
NCT05733566
1,994 pts·Narcolepsy
2017-08→2027-08·Not yet recruiting
1,994 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-08-041.3y awayPh2 Data· Narcolepsy
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P1/2
Not yet…
Catalysts
Ph2 Data
2027-08-04 · 1.3y away
Narcolepsy
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05733566 | Phase 1/2 | Narcolepsy | Not yet recr... | 1994 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-5389 | Roche | Preclinical | RET | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| INC-5849 | Incyte | Phase 2 | PCSK9 | |
| Miritinib | Neurocrine | Phase 3 | TIGIT | |
| Nidasacituzumab | United Therapeutics | Phase 1/2 | TIM-3 |